Which condition is commonly treated with Ipratropium?

Ipratropium is commonly used in the treatment of chronic obstructive pulmonary disease (COPD) due to its mechanism of action as an anticholinergic bronchodilator. It works by inhibiting the action of acetylcholine on muscarinic receptors in the bronchial smooth muscle, leading to relaxation of the airway and improved airflow. This effect is particularly beneficial for patients with COPD, who often experience gradual narrowing of the airways and airflow limitation.

While Ipratropium can be used in combination with beta-agonists and other medications for asthma, its main indication is in the management of COPD. In the case of allergic rhinitis, other agents like antihistamines or nasal corticosteroids are typically preferred. For respiratory infections, treatments focus more on addressing the underlying infection, rather than using bronchodilators like Ipratropium alone. Hence, the primary indication for Ipratropium is centered around the management of COPD, making it the correct choice in this context.